2,2-difluoro-2-(4-methoxyphenyl)acetaldehyde | 362610-07-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,2-difluoro-2-(4-methoxyphenyl)acetaldehyde
• 英文别名: (4-Methoxyphenyl)difluoroacetaldehyde
• CAS: 362610-07-9
• 化学式: C₉H₈F₂O₂
• 分子量: 186.158
• InChiKey: ILBDULKGHXSAHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,2-difluoro-2-(4-methoxyphenyl)acetaldehyde 在 盐酸 、 ammonium hydroxide 、 sodium disulfite 、 碳酸氢钠 、 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 、 异丙醇 为溶剂， 生成 2-amino-3,3-difluoro-3-(4-methoxyphenyl)propionic acid
  参考文献：
  名称：

  α-氧代-β-苯基丙酸和苯丙氨酸的β，β-二氟类似物

  摘要：

  一个简单的三步过程将容易获得的（2-溴-1,1-二氟乙基）芳烃（2）转化为α-芳基-α，α-二氟乙醛（1）。随后的氢氰化，水解，氧化和再次水解得到β-芳基-β，β-二氟-α-氧代丙酸（3）。还原胺化将含氧酸3转化为可分离的α-羟酸11和外消旋β，β-二氟-β-苯丙氨酸衍生物的混合物（4）。对映体纯β，β-difluorophenylalanine（1- 4A得到）时α，α-二氟- α-phenylacet醛（1A）与高手性1-苯基乙胺缩合，将氰化氢加至所得的亚胺中，由此产生的非对映异构体混合物水解为羧酰胺（15），发现可通过分步结晶或色谱法分离。测量了β-芳基-β，β-二氟丙氨酸（4）的p K a值，并探查了后者的生物学特性。3-（4-氯苯基）-3,3-二氟-2-氧代丙酸（4c）被证明是有效的（K i 27μM）和选择性抑制剂Arogenate脱水酶，后者是催化苯丙氨酸生物合成最后一步的关键酶。

  DOI：

  10.1016/j.tet.2004.06.086
• 作为产物：
  描述：

  1-(2-bromo-1,1-difluoroethyl)-4-methoxybenzene 在 sodium hydroxide 、 18-冠醚-6 、 戴斯-马丁氧化剂 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 2,2-difluoro-2-(4-methoxyphenyl)acetaldehyde
  参考文献：
  名称：

  α-氧代-β-苯基丙酸和苯丙氨酸的β，β-二氟类似物

  摘要：

  一个简单的三步过程将容易获得的（2-溴-1,1-二氟乙基）芳烃（2）转化为α-芳基-α，α-二氟乙醛（1）。随后的氢氰化，水解，氧化和再次水解得到β-芳基-β，β-二氟-α-氧代丙酸（3）。还原胺化将含氧酸3转化为可分离的α-羟酸11和外消旋β，β-二氟-β-苯丙氨酸衍生物的混合物（4）。对映体纯β，β-difluorophenylalanine（1- 4A得到）时α，α-二氟- α-phenylacet醛（1A）与高手性1-苯基乙胺缩合，将氰化氢加至所得的亚胺中，由此产生的非对映异构体混合物水解为羧酰胺（15），发现可通过分步结晶或色谱法分离。测量了β-芳基-β，β-二氟丙氨酸（4）的p K a值，并探查了后者的生物学特性。3-（4-氯苯基）-3,3-二氟-2-氧代丙酸（4c）被证明是有效的（K i 27μM）和选择性抑制剂Arogenate脱水酶，后者是催化苯丙氨酸生物合成最后一步的关键酶。

  DOI：

  10.1016/j.tet.2004.06.086

文献信息

• Pd-Catalyzed α-Arylation of Trimethylsilyl Enolates of α,α-Difluoroacetamides
  作者：Shaozhong Ge、Sophie I. Arlow、Michael G. Mormino、John F. Hartwig

  DOI：10.1021/ja508590k

  日期：2014.10.15

  ilyl)acetamides with aryl and heteroaryl bromides catalyzed by an air- and moisture-stable palladacyclic complex containing P(t-Bu)2Cy as ligand. A broad range of electronically varied aryl and heteroaryl bromides underwent this transformation to afford α-aryl-α,α-difluoroacetamides in high yields. Due to the electrophilicity of the fluorinated amide, this palladium-catalyzed cross-coupling reaction

  我们报道了由含有 P(t-Bu)2Cy 作为配体的空气和湿气稳定的钯环配合物催化的 α,α-二氟-α-(三甲基硅基)乙酰胺与芳基和杂芳基溴的芳基化和杂芳基化。多种电子变化的芳基和杂芳基溴化物经历了这种转化，以高产率提供 α-芳基-α,α-二氟乙酰胺。由于氟化酰胺的亲电性，这种钯催化的交叉偶联反应提供了一个通用平台来生成一系列 α,α-二氟羰基化合物，例如 α-芳基-α,α-二氟酮、-乙醛、-在温和条件下，可以制备乙酸酯、乙酸和二氟烷基衍生物，例如2-芳基-2,2-二氟乙醇和乙胺。
• [EN] CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA CÉRAMIDE GALACTOSYLTRANSFÉRASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2018118838A1

  公开（公告）日：2018-06-28

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与酶神经鞘糖脂转移酶（CGT）相关的疾病或紊乱的方法，例如溶酶体贮积症。溶酶体贮积症的例子包括 Krabbe 病和白质变性白血病。
• Polyfluoroether Derivatives via Nucleophilic Fluorination of Glyoxal Hydrates with Deoxofluor
  作者：Rajendra P. Singh、Brendan Twamley、Jean'ne M. Shreeve

  DOI：10.1021/jo016245r

  日期：2002.3.1

  Various glyoxal hydrates have been reacted with Deoxofluor [(CH3OCH2CH2)(2)NSF3]. In concentrated solutions of dichloromethane, Deoxofluor (1) efficiently fluorinates a variety of glyoxal hydrates, RCOCHO.H2O (R = 4-methoxyphenyl, 3,4-methylenedioxyphenyl, 4-methylphenyl, 4-fluorophenyl, phenyl, 2-thienyl, methyl) (6a-g) to form polyfluoroethers 7a-g and 8a-g as meso and racemic mixtures (similar to1:1) in good yields. The meso and racemic compounds were separated by flash chromatography and characterized. When the reactant comprised two different. glyoxal hydrates, mixed polyfluoroethers (9h-j) were observed as the major products. The yields of the mixed polyfluoroethers depend on the ratio of the two different glyoxal hydrates used. Reactions of some other hydrates, such as hydrindantin dehydrate (10) and 1,1,1,5,5,5-hexafluoro-2,2,4,4-pentanetetrol (11), were also studied with Deoxofluor to give a cyclic polyfluoroether (12) and beta-ketoamine (13), respectively. When the reactions of 6a-d were carried out under very dilute conditions, difluoro aldehydes (14a-d) or tetrafluoroalkanes (15a-d) were formed rather than polyfluoroethers. Reactions of concentrated solutions of nonhydrated glyoxals (16k-m) in methylene chloride with Deoxofluor produced the tetrafluoroalkanes (18k-m) in good yields with only trace amounts of difluoroaldehydes (17k-m) being found. The structures of 7a (meso), 8b (racemic), and 12 have been confirmed by single-crystal X-ray analysis.
• Concentration-Dependent Reactions of Deoxofluor with Arylglyoxal Hydrates:  A New Route to Polyfluoro Ethers
  作者：Rajendra P. Singh、Jean'ne M. Shreeve

  DOI：10.1021/ol016319l

  日期：2001.8.1

  [GRAPHICS]In concentrated solutions (CH2Cl2) at 25 degreesC, arylglyoxal hydrates, ArCOCHO .H2O (Ar = 3,4-OCH2O-C6H3-, 4-MeO-C6H4-, 4-Me-C6H4-, 4-F-C6H4-, Ph-, S-CH=CH-CH=C-) (2a-f) with Deoxofluor gave fluorinated ethers, ArCF2CHFOCHFCF2Ar, (3a-f) in > 90% yields as meso/racemic mixtures (similar to1:1). Under very dilute conditions, mixtures of ArCF2CHO (major) (4a-f) and ArCF2CF2H (6a-f) (minor) were obtained. The structures of 3b (racemic) and 4a (meso) have been confirmed by single-crystal X-ray analysis.
• CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE
  申请人：BioMarin Pharmaceutical Inc.

  公开号：US20190322676A1

  公开（公告）日：2019-10-24

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.